이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

새로 진단된 II기-IV기 또는 재발성 I기 상피성 난소 또는 나팔관암 환자 치료에서 1차 요법으로 베바시주맙을 병용하거나 병용하지 않는 카보플라틴 및 파클리탁셀 또는 옥살리플라틴 및 카페시타빈

2026년 11월 11일 업데이트: National Cancer Institute (NCI)

오픈 라벨 카보플라틴 및 파클리탁셀 +/- NCI 제공 제제: 베바시주맙(NSC #704865)의 GCIG 그룹간 다기관 다기관 3상 시험, 점액성 상피성 난소암 또는 나팔관암 환자의 1차 화학요법으로서 옥살리플라틴 및 카페시타빈 +/- 베바시주맙과 비교 (MEOC)

This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II-IV, or recurrent (has come back) stage I epithelial ovarian or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known which regimen of combination chemotherapy given together with or without bevacizumab is more effective in treating epithelial ovarian cancer or fallopian tube cancer.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.

II. To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.

SECONDARY OBJECTIVES:

I. To determine if capecitabine and oxaliplatin increases the duration of progression-free survival (PFS) compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.

II. To determine if bevacizumab increases the duration of PFS compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.

III. To compare the response rates for capecitabine and oxaliplatin versus carboplatin and paclitaxel in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.

IV. To compare the response rates for bevacizumab versus no bevacizumab in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.

V. To determine the nature and degree of toxicity of capecitabine and oxaliplatin compared with that of carboplatin and paclitaxel in this cohort of patients.

VI. To determine the nature and degree of toxicity of bevacizumab in this cohort of patients.

VII. To compare capecitabine and oxaliplatin versus carboplatin and paclitaxel with respect to changes in patient reported neurotoxicity.

VIII. To determine the impact on quality of life (QOL, as measured by the Functional Assessment of Cancer Therapy-Ovarian [FACT-O] Trial Outcome Index [TOI]) following treatment with the above regimens.

TERTIARY OBJECTIVES:

I. To collect fixed and/or frozen tissue and whole blood for future research studies.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I: Patients receive carboplatin intravenously (IV) over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.

ARM IV: Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.

After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

연구 유형

중재적

등록 (실제)

50

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • University of Alabama at Birmingham Cancer Center
      • Mobile, Alabama, 미국, 36688
        • University of South Alabama Mitchell Cancer Institute
    • Arizona
      • Phoenix, Arizona, 미국, 85013
        • Saint Joseph's Hospital and Medical Center
    • Arkansas
      • Jonesboro, Arkansas, 미국, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Burbank, California, 미국, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Castro Valley, California, 미국, 94546
        • East Bay Radiation Oncology Center
      • Castro Valley, California, 미국, 94546
        • Valley Medical Oncology Consultants-Castro Valley
      • Emeryville, California, 미국, 94608
        • Bay Area Breast Surgeons Inc
      • Emeryville, California, 미국, 94608
        • Epic Care Partners in Cancer Care
      • Fremont, California, 미국, 94538
        • Valley Medical Oncology Consultants-Fremont
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90033
        • Los Angeles General Medical Center
      • Martinez, California, 미국, 94553-3156
        • Contra Costa Regional Medical Center
      • Mountain View, California, 미국, 94040
        • El Camino Hospital
      • Oakland, California, 미국, 94609
        • Alta Bates Summit Medical Center - Summit Campus
      • Oakland, California, 미국, 94609
        • Hematology and Oncology Associates-Oakland
      • Oakland, California, 미국, 94609
        • Tom K Lee Inc
      • Oakland, California, 미국, 94609
        • Bay Area Tumor Institute
      • Oakland, California, 미국, 94602
        • Wilma Chan Highland Hospital
      • Orange, California, 미국, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • San Pablo, California, 미국, 94806
        • Doctors Medical Center- JC Robinson Regional Cancer Center
      • Sylmar, California, 미국, 91342
        • Olive View-University of California Los Angeles Medical Center
    • Colorado
      • Aurora, Colorado, 미국, 80012
        • The Medical Center of Aurora
      • Aurora, Colorado, 미국, 80045
        • UCHealth University of Colorado Hospital
      • Boulder, Colorado, 미국, 80303
        • Boulder Community Foothills Hospital
      • Colorado Springs, Colorado, 미국, 80907
        • Penrose-Saint Francis Healthcare
      • Denver, Colorado, 미국, 80218
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, 미국, 80220
        • Rose Medical Center
      • Denver, Colorado, 미국, 80222
        • Western States Cancer Research NCORP
      • Denver, Colorado, 미국, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, 미국, 80210
        • AdventHealth Porter
      • Englewood, Colorado, 미국, 80113
        • Swedish Medical Center
      • Fort Collins, Colorado, 미국, 80524
        • Poudre Valley Hospital
      • Grand Junction, Colorado, 미국, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, 미국, 80631
        • Banner North Colorado Medical Center
      • Lakewood, Colorado, 미국, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, 미국, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, 미국, 80124
        • Sky Ridge Medical Center
      • Longmont, Colorado, 미국, 80501
        • Longmont United Hospital
      • Loveland, Colorado, 미국, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, 미국, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, 미국, 81004
        • Saint Mary Corwin Medical Center
      • Thornton, Colorado, 미국, 80229
        • North Suburban Medical Center
      • Wheat Ridge, Colorado, 미국, 80401
        • Intermountain Health Lutheran Hospital
    • Connecticut
      • Hartford, Connecticut, 미국, 06102
        • Hartford Hospital
      • New Britain, Connecticut, 미국, 06050
        • The Hospital of Central Connecticut
      • Stamford, Connecticut, 미국, 06904
        • Stamford Hospital/Bennett Cancer Center
    • Delaware
      • Lewes, Delaware, 미국, 19958
        • Beebe Medical Center
      • Newark, Delaware, 미국, 19718
        • Christiana Care Health System-Christiana Hospital
    • Florida
      • Gainesville, Florida, 미국, 32610
        • UF Health Cancer Institute - Gainesville
      • Orlando, Florida, 미국, 32803
        • AdventHealth Orlando
    • Georgia
      • Augusta, Georgia, 미국, 30912
        • Augusta University Medical Center
      • Columbus, Georgia, 미국, 31904
        • John B Amos Cancer Center
      • Gainesville, Georgia, 미국, 30501
        • Northeast Georgia Medical Center-Gainesville
      • Savannah, Georgia, 미국, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu, Hawaii, 미국, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, 미국, 96813
        • University of Hawaii Cancer Center
      • Honolulu, Hawaii, 미국, 96826
        • Kapiolani Medical Center for Women and Children
    • Illinois
      • Bloomington, Illinois, 미국, 61704
        • Illinois CancerCare-Bloomington
      • Bloomington, Illinois, 미국, 61701
        • OSF Saint Joseph Medical Center
      • Canton, Illinois, 미국, 61520
        • Illinois CancerCare-Canton
      • Canton, Illinois, 미국, 61520
        • Graham Hospital Association
      • Carthage, Illinois, 미국, 62321
        • Illinois CancerCare-Carthage
      • Carthage, Illinois, 미국, 62321
        • Memorial Hospital
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Decatur, Illinois, 미국, 62526
        • Heartland Cancer Research NCORP
      • Eureka, Illinois, 미국, 61530
        • Illinois CancerCare-Eureka
      • Eureka, Illinois, 미국, 61530
        • Eureka Hospital
      • Galesburg, Illinois, 미국, 61401
        • Illinois CancerCare-Galesburg
      • Havana, Illinois, 미국, 62644
        • Mason District Hospital
      • Havana, Illinois, 미국, 62644
        • Illinois CancerCare-Havana
      • Hinsdale, Illinois, 미국, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, 미국, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, 미국, 61455
        • Illinois CancerCare-Macomb
      • Macomb, Illinois, 미국, 61455
        • Mcdonough District Hospital
      • Monmouth, Illinois, 미국, 61462
        • Illinois CancerCare-Monmouth
      • Monmouth, Illinois, 미국, 61462
        • Holy Family Medical Center
      • Normal, Illinois, 미국, 61761
        • Carle Cancer Institute Normal
      • Normal, Illinois, 미국, 61761
        • Illinois CancerCare-Community Cancer Center
      • Normal, Illinois, 미국, 61761
        • Carle BroMenn Medical Center
      • Ottawa, Illinois, 미국, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Ottawa, Illinois, 미국, 61350
        • Ottawa Regional Hospital and Healthcare Center
      • Pekin, Illinois, 미국, 61554
        • Illinois CancerCare-Pekin
      • Pekin, Illinois, 미국, 61554
        • OSF Saint Francis Radiation Oncology at Pekin
      • Peoria, Illinois, 미국, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, 미국, 61637
        • OSF Saint Francis Medical Center
      • Peoria, Illinois, 미국, 61615
        • Illinois CancerCare-Peoria
      • Peoria, Illinois, 미국, 61614
        • Proctor Hospital
      • Peru, Illinois, 미국, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, 미국, 61354
        • Illinois Valley Hospital
      • Princeton, Illinois, 미국, 61356
        • Illinois CancerCare-Princeton
      • Princeton, Illinois, 미국, 61356
        • Perry Memorial Hospital
      • Rockford, Illinois, 미국, 61104
        • Swedish American Hospital
      • Spring Valley, Illinois, 미국, 61362
        • Illinois CancerCare-Spring Valley
    • Indiana
      • Elkhart, Indiana, 미국, 46515
        • Elkhart General Hospital
      • Elkhart, Indiana, 미국, 46514
        • Michiana Hematology Oncology PC-Elkhart
      • Elkhart, Indiana, 미국, 46514-2098
        • Elkhart Clinic
      • Indianapolis, Indiana, 미국, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, 미국, 46260
        • Ascension Saint Vincent Indianapolis Hospital
      • Kokomo, Indiana, 미국, 46904
        • Community Howard Regional Health
      • La Porte, Indiana, 미국, 46350
        • IU Health La Porte Hospital
      • Mishawaka, Indiana, 미국, 46545
        • Michiana Hematology Oncology PC-Mishawaka
      • Mishawaka, Indiana, 미국, 46545
        • Cancer Care Partners LLC
      • Mishawaka, Indiana, 미국, 46545
        • Saint Joseph Regional Medical Center-Mishawaka
      • Plymouth, Indiana, 미국, 46563
        • Michiana Hematology Oncology PC-Plymouth
      • South Bend, Indiana, 미국, 46601
        • Memorial Hospital of South Bend
      • South Bend, Indiana, 미국, 46628
        • Northern Indiana Cancer Research Consortium
      • South Bend, Indiana, 미국, 46617
        • South Bend Clinic
      • Westville, Indiana, 미국, 46391
        • Michiana Hematology Oncology PC-Westville
    • Iowa
      • Clive, Iowa, 미국, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, 미국, 50309
        • Iowa-Wide Oncology Research Coalition NCORP
      • Des Moines, Iowa, 미국, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Sioux City, Iowa, 미국, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, 미국, 51102
        • Mercy Medical Center-Sioux City
      • Sioux City, Iowa, 미국, 51104
        • Saint Luke's Regional Medical Center
      • West Des Moines, Iowa, 미국, 50266-7700
        • Methodist West Hospital
      • West Des Moines, Iowa, 미국, 50266
        • Mercy Medical Center-West Lakes
    • Kentucky
      • Edgewood, Kentucky, 미국, 41017
        • Saint Elizabeth Healthcare Edgewood
      • Lexington, Kentucky, 미국, 40536
        • University of Kentucky/Markey Cancer Center
      • Pikeville, Kentucky, 미국, 41501
        • Pikeville Medical Center
    • Louisiana
      • Lafayette, Louisiana, 미국, 70503
        • Cancer Center of Acadiana
      • New Orleans, Louisiana, 미국, 70121
        • Ochsner Medical Center Jefferson
    • Maryland
      • Baltimore, Maryland, 미국, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, 미국, 20889-5600
        • Walter Reed National Military Medical Center
      • Elkton, Maryland, 미국, 21921
        • Christiana Care - Union Hospital
    • Massachusetts
      • Springfield, Massachusetts, 미국, 01199
        • Baystate Medical Center
    • Michigan
      • Escanaba, Michigan, 미국, 49829
        • OSF Saint Francis Hospital and Medical Group
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, 미국, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, 미국, 49048
        • Beacon Kalamazoo
      • Niles, Michigan, 미국, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Saint Joseph, Michigan, 미국, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, 미국, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Cape Girardeau, Missouri, 미국, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Jefferson City, Missouri, 미국, 65109
        • MU Health Care Goldschmidt Cancer Center
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, 미국, 63131
        • Missouri Baptist Medical Center
    • Montana
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, 미국, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, 미국, 59102
        • Montana Cancer Consortium NCORP
      • Billings, Montana, 미국, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconess Hospital
      • Butte, Montana, 미국, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, 미국, 59405
        • Great Falls Clinic
      • Great Falls, Montana, 미국, 59405
        • Benefis Sletten Cancer Institute
      • Havre, Montana, 미국, 59501
        • Northern Montana Hospital
      • Helena, Montana, 미국, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, 미국, 59901
        • Glacier Oncology PLLC
      • Kalispell, Montana, 미국, 59901
        • Kalispell Medical Oncology
      • Kalispell, Montana, 미국, 59901
        • Logan Health Medical Center
      • Missoula, Montana, 미국, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, 미국, 59802
        • Montana Cancer Specialists
    • Nebraska
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, 미국, 89106
        • Women's Cancer Center of Nevada
    • New Jersey
      • Camden, New Jersey, 미국, 08103
        • Cooper Hospital University Medical Center
      • Mount Holly, New Jersey, 미국, 08060
        • Virtua Memorial
      • Voorhees Township, New Jersey, 미국, 08043
        • Virtua Voorhees
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87106
        • Southwest Gynecologic Oncology Associates Inc
      • Albuquerque, New Mexico, 미국, 87106
        • University of New Mexico Cancer Center
    • New York
      • Stony Brook, New York, 미국, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, 미국, 13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Durham, North Carolina, 미국, 27710
        • Duke University Medical Center
      • Goldsboro, North Carolina, 미국, 27534
        • Wayne Memorial Hospital
      • Hendersonville, North Carolina, 미국, 28792
        • AdventHealth Hendersonville
      • Winston-Salem, North Carolina, 미국, 27157
        • Wake Forest University Health Sciences
      • Winston-Salem, North Carolina, 미국, 27104
        • Southeast Clinical Oncology Research Consortium NCORP
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Bismarck, North Dakota, 미국, 58501
        • Mid Dakota Clinic
      • Bismarck, North Dakota, 미국, 58501
        • Saint Alexius Medical Center
    • Ohio
      • Akron, Ohio, 미국, 44304
        • Summa Health System - Akron Campus
      • Bellefontaine, Ohio, 미국, 43311
        • Mary Rutan Hospital
      • Canton, Ohio, 미국, 44710
        • Aultman Health Foundation
      • Chillicothe, Ohio, 미국, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, 미국, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cincinnati, Ohio, 미국, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, 미국, 45242
        • Bethesda North Hospital
      • Cleveland, Ohio, 미국, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, 미국, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, 미국, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, 미국, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, 미국, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, 미국, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, 미국, 43228
        • Doctors Hospital
      • Columbus, Ohio, 미국, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, 미국, 43215
        • Grant Medical Center
      • Columbus, Ohio, 미국, 43222
        • Mount Carmel Health Center West
      • Columbus, Ohio, 미국, 43215
        • Columbus NCI Community Oncology Research Program
      • Delaware, Ohio, 미국, 43015
        • Grady Memorial Hospital
      • Kettering, Ohio, 미국, 45429
        • Kettering Medical Center
      • Lancaster, Ohio, 미국, 43130
        • Fairfield Medical Center
      • Marietta, Ohio, 미국, 45750
        • Marietta Memorial Hospital
      • Mayfield Heights, Ohio, 미국, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, 미국, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, 미국, 43050
        • Knox Community Hospital
      • Newark, Ohio, 미국, 43055
        • Licking Memorial Hospital
      • Portsmouth, Ohio, 미국, 45662
        • Southern Ohio Medical Center
      • Springfield, Ohio, 미국, 45504
        • Springfield Regional Medical Center
      • Westerville, Ohio, 미국, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, 미국, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, 미국, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Pennsylvania
      • Abington, Pennsylvania, 미국, 19001
        • Jefferson Abington Hospital
      • Bethlehem, Pennsylvania, 미국, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Medical Center
      • Hazleton, Pennsylvania, 미국, 18201
        • Geisinger Medical Center-Cancer Center Hazleton
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC Hillman Cancer Center
      • State College, Pennsylvania, 미국, 16801
        • Geisinger Medical Group
      • Wilkes-Barre, Pennsylvania, 미국, 18711
        • Geisinger Wyoming Valley/Henry Cancer Center
    • Rhode Island
      • Providence, Rhode Island, 미국, 02905
        • Women and Infants Hospital
    • South Carolina
      • Anderson, South Carolina, 미국, 29621
        • AnMed Health Cancer Center
      • Anderson, South Carolina, 미국, 29621
        • AnMed Health Hospital
      • Greenville, South Carolina, 미국, 29601
        • Saint Francis Hospital
      • Spartanburg, South Carolina, 미국, 29303
        • Spartanburg Medical Center
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, 미국, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Knoxville, Tennessee, 미국, 37920
        • University of Tennessee - Knoxville
    • Texas
      • Dallas, Texas, 미국, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, 미국, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Galveston, Texas, 미국, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, 미국, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, 미국, 77030
        • Houston Methodist Hospital
      • Houston, Texas, 미국, 77030
        • Memorial Hermann Texas Medical Center
    • Virginia
      • Danville, Virginia, 미국, 24541
        • Danville Regional Medical Center
      • Fredericksburg, Virginia, 미국, 22408
        • Hematology Oncology Associates of Fredericksburg Inc
      • Lynchburg, Virginia, 미국, 24501
        • Centra Alan B Pearson Regional Cancer Center
    • Wisconsin
      • Green Bay, Wisconsin, 미국, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, 미국, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • Green Bay, Wisconsin, 미국, 54301-3526
        • Green Bay Oncology at Saint Vincent Hospital
      • La Crosse, Wisconsin, 미국, 54601
        • Gundersen Lutheran Medical Center
      • Manitowoc, Wisconsin, 미국, 54221
        • Holy Family Memorial Hospital
      • Marinette, Wisconsin, 미국, 54143
        • Bay Area Medical Center
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, 미국, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, 미국, 53233
        • Aurora Sinai Medical Center
      • Oconto Falls, Wisconsin, 미국, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Sheboygan, Wisconsin, 미국, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Summit, Wisconsin, 미국, 53066
        • Aurora Medical Center in Summit
      • West Allis, Wisconsin, 미국, 53227
        • Aurora West Allis Medical Center
    • Wyoming
      • Casper, Wyoming, 미국, 82609
        • Rocky Mountain Oncology
      • Sheridan, Wyoming, 미국, 82801
        • Welch Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Patients with a histologic diagnosis of mucinous adenocarcinoma of the ovary or fallopian tube with either optimal (=< 1 cm residual disease) or suboptimal residual disease following initial surgery; patients may have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or no measurable disease
  • All patients must have had appropriate surgery including appendectomy (unless patient has history of prior appendectomy) for ovarian or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage
  • Patients must have stage II-IV disease (new or recurrent-chemonaïve; no brain metastasis) or recurrent stage I disease (chemonaïve)
  • Newly diagnosed patients must begin protocol therapy within 10 weeks of primary debulking; for stage I recurrent patients (chemonaïve), they should begin protocol therapy within 14 days of randomization
  • Patients must have a negative colonoscopy within 1 year of enrolling in the study
  • Absolute neutrophil count (ANC) >= 1,500/mcl
  • White blood cell (WBC) count >= 3,000/mcl
  • Platelets >= 100,000/mcl
  • Hemoglobin (Hgb) >= 10 g/dl (can be post transfusion)
  • Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) OR creatinine clearance > 50 cc/min
  • Bilirubin =< 1.5 x ULN
  • Serum glutamic oxaloacetic transaminase (SGOT) =< to 2.5 x ULN
  • Alkaline phosphatase =< to 2.5 x ULN
  • Neuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1
  • Urine dipstick for proteinuria < 2+; if urine dipstick is >= 2+, 24 hour urine must demonstrate =< 1 g protein in 24 hours OR patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
  • Prothrombin time (PT) =< 1.5 x ULN
  • Activated prothrombin time (APTT) =< 1.5 x ULN
  • Patients of childbearing potential must agree to practice an effective form of birth control during study treatment and for six months after completion of treatment
  • Patients who have met the pre-entry requirements
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information
  • Patients with Gynecologic Oncology Group (GOG) performance grade of 0, 1 or 2
  • Patients with life expectancy > 3 months

Exclusion Criteria:

  • Patients with known colon cancer or history of colon cancer
  • Patients with primary peritoneal carcinoma
  • Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
  • Patients who have received chemotherapy, radiotherapy or any investigational treatment for a gynecologic cancer (does include breast cancer) or colorectal cancer prior to enrollment
  • Patients with a major surgical procedure anticipated during the course of the study; this includes but is not limited to: abdominal surgery (laparotomy or laparoscopy) such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery; please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
  • Patients may have minor surgical procedures (i.e., mediport insertion) fine needle aspiration or core biopsies as long as it is performed > 7 days prior to the first date of bevacizumab therapy and there is no evidence of wound disruption or impaired healing
  • Patients with surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for fact that bevacizumab can be omitted from first cycle of chemotherapy)
  • Patients with a history of abdominal fistula or perforation within the past 12 months
  • Patients with a current, serious, non-healing wound, ulcer, or bone fracture; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
  • Patients with known hypersensitivity to Chinese hamster cell products or other recombinant human or humanized antibodies
  • Patients with mixed epithelial ovarian cancer histology
  • Patients with tumors of low malignant potential
  • History or evidence of upon physical examination of central nervous system (CNS) disease, including history of primary brain tumor or any history of brain metastases, or seizures not controlled with standard medical therapy
  • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 100 mm Hg; patients with a history of hypertension are permitted
  • Myocardial infarction or unstable angina within 12 months of the first date of bevacizumab therapy
  • New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication; women who have received prior treatment with anthracycline (including doxorubicin and/or liposomal doxorubicin) and have an ejection fraction < 50% will be excluded from the study
  • Grade 1, category 2 or greater, peripheral vascular disease; patient cannot have anything worse than mild, symptomatic claudication with exercise
  • History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of bevacizumab therapy
  • History of pulmonary embolism or deep vein thrombosis in the past 6 months
  • Previous history of malabsorption or other conditions preventing oral treatment
  • Patients who are pregnant or nursing
  • Patients with acute hepatitis or active infection that requires parenteral antibiotics
  • Patients with active bleeding or pathologic conditions that carry a high risk of bleeding such as a known bleeding disorder, coagulopathy or tumor involving the major vessels
  • Patients taking warfarin

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I (carboplatin and paclitaxel)

Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV

다른 이름들:
  • 탁솔
  • 안자탁스
  • 아소탁스
  • 브리스타솔
  • 프락셀
  • 탁솔 콘첸트라트

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가
실험적: Arm II (oxaliplatin and capecitabine)

Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Given PO

다른 이름들:
  • 젤로다
  • Ro 09-1978/000

Given IV

다른 이름들:
  • 1-OHP
  • 다코틴
  • 닥플라
  • 엘록사틴
  • 아이 헹
  • 아이헝
  • 디아미노시클로헥산 옥살라토백금
  • JM-83
  • 옥살라토플라틴
  • 옥살라토백금
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • 엘플라트
  • JM 83
  • JM83
  • RP54780
  • SR 96669
실험적: Arm III (carboplatin, paclitaxel, bevacizumab)

Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV

다른 이름들:
  • 탁솔
  • 안자탁스
  • 아소탁스
  • 브리스타솔
  • 프락셀
  • 탁솔 콘첸트라트

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Given IV

다른 이름들:
  • 아바스틴
  • ABP 215
  • 안티-VEGF
  • 항-VEGF 인간화 단클론항체
  • 항-VEGF 단클론항체 SIBP04
  • 항-VEGF rhuMAb
  • 베바시주맙
  • 베바시주맙 바이오시밀러 ABP 215
  • 베바시주맙 바이오시밀러 BEVZ92
  • 베바시주맙 바이오시밀러 BI 695502
  • 베바시주맙 바이오시밀러 CBT 124
  • 베바시주맙 바이오시밀러 CT-P16
  • 베바시주맙 바이오시밀러 FKB238
  • 베바시주맙 바이오시밀러 GB-222
  • 베바시주맙 바이오시밀러 HD204
  • 베바시주맙 바이오시밀러 HLX04
  • 베바시주맙 바이오시밀러 IBI305
  • 베바시주맙 바이오시밀러 LY01008
  • 베바시주맙 바이오시밀러 MIL60
  • 베바시주맙 바이오시밀러 음바시
  • 베바시주맙 바이오시밀러 MYL-1402O
  • 베바시주맙 바이오시밀러 QL 1101
  • 베바시주맙 바이오시밀러 RPH-001
  • 베바시주맙 바이오시밀러 SCT501
  • 베바시주맙 바이오시밀러 지라베브
  • 베바시주맙-awwb
  • 베바시주맙-bvzr
  • BP102
  • BP102 바이오시밀러
  • HD204
  • 면역글로불린 G1(Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF 경쇄, 이합체
  • 음바시
  • MYL-1402O
  • 재조합 인간화 항-VEGF 단클론 항체
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • 지라베프
  • 아베그라
  • QL1101
  • IBI305
  • 비바스다
  • 베바시주맙 바이오시밀러 QL1101
  • 박쥐1706
  • 박쥐 1706
  • BAT-1706
  • BAT1706 바이오시밀러
  • 베바시주맙 바이오시밀러 BAT1706
  • 베바시주맙-adcd
  • CT-P16
  • 베그젤마
  • 알림시스
  • ABP-215
  • ABP215
  • 아이빈티오
  • 베바시주맙-아이비
  • 베바시주맙-에퀴
  • 베바시주맙-말리
  • 베바시주맙-온베
  • CT P16
  • CTP16
  • 등가
  • 온베브지
  • 아브지비
  • 베바시주맙 바이오시밀러 MB02
  • 베바시주맙-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • 오야바스
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305
실험적: Arm IV (oxaliplatin, capecitabine, bevacizumab)

Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Given IV

다른 이름들:
  • 아바스틴
  • ABP 215
  • 안티-VEGF
  • 항-VEGF 인간화 단클론항체
  • 항-VEGF 단클론항체 SIBP04
  • 항-VEGF rhuMAb
  • 베바시주맙
  • 베바시주맙 바이오시밀러 ABP 215
  • 베바시주맙 바이오시밀러 BEVZ92
  • 베바시주맙 바이오시밀러 BI 695502
  • 베바시주맙 바이오시밀러 CBT 124
  • 베바시주맙 바이오시밀러 CT-P16
  • 베바시주맙 바이오시밀러 FKB238
  • 베바시주맙 바이오시밀러 GB-222
  • 베바시주맙 바이오시밀러 HD204
  • 베바시주맙 바이오시밀러 HLX04
  • 베바시주맙 바이오시밀러 IBI305
  • 베바시주맙 바이오시밀러 LY01008
  • 베바시주맙 바이오시밀러 MIL60
  • 베바시주맙 바이오시밀러 음바시
  • 베바시주맙 바이오시밀러 MYL-1402O
  • 베바시주맙 바이오시밀러 QL 1101
  • 베바시주맙 바이오시밀러 RPH-001
  • 베바시주맙 바이오시밀러 SCT501
  • 베바시주맙 바이오시밀러 지라베브
  • 베바시주맙-awwb
  • 베바시주맙-bvzr
  • BP102
  • BP102 바이오시밀러
  • HD204
  • 면역글로불린 G1(Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF 경쇄, 이합체
  • 음바시
  • MYL-1402O
  • 재조합 인간화 항-VEGF 단클론 항체
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • 지라베프
  • 아베그라
  • QL1101
  • IBI305
  • 비바스다
  • 베바시주맙 바이오시밀러 QL1101
  • 박쥐1706
  • 박쥐 1706
  • BAT-1706
  • BAT1706 바이오시밀러
  • 베바시주맙 바이오시밀러 BAT1706
  • 베바시주맙-adcd
  • CT-P16
  • 베그젤마
  • 알림시스
  • ABP-215
  • ABP215
  • 아이빈티오
  • 베바시주맙-아이비
  • 베바시주맙-에퀴
  • 베바시주맙-말리
  • 베바시주맙-온베
  • CT P16
  • CTP16
  • 등가
  • 온베브지
  • 아브지비
  • 베바시주맙 바이오시밀러 MB02
  • 베바시주맙-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • 오야바스
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given PO

다른 이름들:
  • 젤로다
  • Ro 09-1978/000

Given IV

다른 이름들:
  • 1-OHP
  • 다코틴
  • 닥플라
  • 엘록사틴
  • 아이 헹
  • 아이헝
  • 디아미노시클로헥산 옥살라토백금
  • JM-83
  • 옥살라토플라틴
  • 옥살라토백금
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • 엘플라트
  • JM 83
  • JM83
  • RP54780
  • SR 96669

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival
기간: Up to five years

Overall survival is defined as the duration of time from study entry to time of death, or the date of last contact.

Up to five years

2차 결과 측정

결과 측정
측정값 설명
기간
Participants With Grade 1 or Higher Non-serious Adverse Effects Assessed by CTCAE Version 4.0
기간: Every cycle while on treatment, up to 5 years

Grade 1 or higher non-serious adverse events were graded by CTC AE v 4.

Every cycle while on treatment, up to 5 years
Progression-free Survival
기간: Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.

Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
Objective Tumor Response
기간: CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years

Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR),.>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR

CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years
Patient Reported Neurotoxicity
기간: baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

Patient reported neurotoxicity symptoms as measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.

baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
Patient Reported Quality of Life
기간: baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

Patient reported quality of life was measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). Each item in the FACT-O TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. The FACT-O TOI score ranges 0-100 with a large score suggests better QOL

baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

기타 결과 측정

결과 측정
측정값 설명
기간
Numbers and Percentages of Patients With Mutations in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Oncogene
기간: Baseline

Will be tabulated. Interactions between the mutational status of the KRAS oncogene and treatment will be examined.

Baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: David M Gershenson, NRG Oncology

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2010년 10월 12일

기본 완료 (실제)

2015년 2월 25일

연구 완료 (추정된)

2027년 3월 12일

연구 등록 날짜

최초 제출

2010년 3월 4일

QC 기준을 충족하는 최초 제출

2010년 3월 4일

처음 게시됨 (추정된)

2010년 3월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2011-02516
  • U10CA180868 (미국 NIH 보조금/계약)
  • U10CA027469 (미국 NIH 보조금/계약)
  • NCI-2011-02516 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • GOG-0241 (기타 식별자: CTEP)
  • CDR0000667089
  • GOG-0241
  • GOG-0241 (기타 식별자: NRG Oncology)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다